Taiho Pharmaceutical Co., Ltd. (TPC), an oncology pharmaceutical company headquartered in Tokyo, has established Taiho Ventures, a strategic corporate venture capital arm of TPC, in California.

Taiho Ventures will be investing globally in the startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. With the support of Taiho's experience in the field of oncology product discovery and development, Taiho Ventures will provide financial resources and company outreach to build strategic alliances to help translate novel research and high-potential drug candidates into cornerstone products. Initially, Taiho Ventures will make investments from the pooled amount of $50 million.

In June 2014, TPC committed to invest $30 million in Remiges BioPharma Fund and through Remiges' well-connected U.S.-Japan cross-border investment team, Taiho has been tapping into the U.S./Europe biotech startup community to catalyze the company's R&D.